Related Experiment Video
Updated: Oct 13, 2025

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
Published on: June 23, 2023
Withdrawal from Long-Term Use of Unusually High-Dose Oxazepam
Antti Mustonen1,2,3, Juhani Leijala3, Johanna Aronranta3
1Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
High-dose benzodiazepine (BZD) misuse requires specialized tapering protocols. This case study details a successful inpatient withdrawal from 1800mg oxazepam, offering a new protocol for clinicians managing severe BZD dependence.
Area of Science:
- Psychiatry
- Pharmacology
- Addiction Medicine
Background:
- Benzodiazepine (BZD) misuse is a significant global health issue.
- High-dose BZD withdrawal is challenging, often requiring inpatient care and facing high relapse rates.
- Existing guidelines inadequately address tapering protocols for exceptionally high BZD doses.
Observation:
- A case of severe dependence on 1800mg daily oxazepam (OXP) is presented.
- A specialized BZD tapering protocol was implemented in an inpatient psychiatric setting.
- Patient outcomes were monitored for three months post-discharge.
Findings:
- The described tapering protocol facilitated successful high-dose oxazepam withdrawal.
- The patient remained abstinent and stable during the three-month follow-up period.
- The protocol offers a potential solution for managing extreme BZD doses.
Implications:
- This case provides a novel tapering strategy for clinicians facing high-dose benzodiazepine dependence.
- The findings may inform the development of more comprehensive BZD withdrawal guidelines.
- Successful management of high-dose BZD withdrawal can reduce associated complications and relapse rates.
More Related Videos
09:29Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
Published on: August 4, 2022
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
Related Concept Videos
CNS Depressants: Barbiturates and Benzodiazepines
Anxiolytic Drugs: Benzodiazepines and Buspirone
CNS Depressants: Alcohol and Nicotine
Drug Dependence
Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...